Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Sutent

The National Institute for Health and Clinical Excellence has recommended Pfizer's Sutent as a possible first line drug treatment for people with advanced and/or metastatic renal cell carcinoma

The National Institute for Health and Clinical Excellence (NICE) has recommended Pfizer's Sutent (sunitinib) as a possible first line drug treatment for people with advanced and/or metastatic renal cell carcinoma. The new guidance applies to mobile patients who are suitable candidates for immunotherapy.  

Sutent was originally reviewed along with Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), and Wyeth's Torisel (temsirolimus) as part of a multiple technology appraisal. In August 2008, NICE advised against the use of all four drugs for this condition, but has since reassessed how it values medicines intended to extend life in terminal patients. In addition, Pfizer has also offered the initial six-week cycle of treatment with Sutent free of charge to the NHS. Guidance on the other three drugs is scheduled to be published in June.

Patient groups have welcomed the decision. Professor Robert Hawkins of Cancer Research UK said in a statement: "I am delighted that Sutent will be available. It will remove a great deal of anxiety and uncertainty for people diagnosed with renal cancer to know that modern, effective treatment is now available to them."

25th March 2009

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...
Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....

Infographics